Hirota T, Takeuchi M, Iwata A, Kitagawa S, Sato T, Konno K, Sawada K, Kobayashi S, Hamaguchi N, Agata H, Katano N, Fujimoto T
Dept. of Pediatrics, Aichi Medical University.
Gan To Kagaku Ryoho. 1998 Feb;25(3):385-90.
Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor. ICE therapy was administered in doses of Ifosfamide 1,800 mg/m2 x 5, Carboplatin 400 mg/m2 x 2 and Etoposide 100 mg/m2 x 5. A total of 30 courses were administered. Two cases of osteosarcoma had a stable disease (range, 3-9 months) and 2 cases of brain tumor had a complete response by magnetic resonance imaging. Moderate or severe toxicity evaluated on a per course basis included: neutropenia 83%, thrombocytopenia 93%, fever 30%, hepatotoxicity 3%, and hemorrhagic cystitis 3%. The median time to hematologic recovery was 20 days. ICE therapy is highly effective for the treatment of refractory or recurrent solid tumors with acceptable toxicity.
异环磷酰胺、卡铂和依托泊苷（ICE）疗法用于治疗4例患者，其中2例为难治性骨肉瘤，1例为复发性脑肿瘤，1例为新诊断的脑肿瘤。ICE疗法的给药剂量为：异环磷酰胺1800mg/m²×5，卡铂400mg/m²×2，依托泊苷100mg/m²×5。共进行了30个疗程。2例骨肉瘤患者病情稳定（持续时间3 - 9个月），2例脑肿瘤患者经磁共振成像显示完全缓解。按每个疗程评估，中度或重度毒性包括：中性粒细胞减少83%，血小板减少93%，发热30%，肝毒性3%，出血性膀胱炎3%。血液学恢复的中位时间为20天。ICE疗法对治疗难治性或复发性实体瘤疗效显著，且毒性可接受。
